(RTTNews) - Bicycle Therapeutics (BCYC) reported financial results for the second quarter that ended on June 30, 2026, reflecting a narrower net loss and provided updates on the progress of its oncology pipeline.
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing Bicycle molecules, a class of synthetic medicines designed to precisely target disease-related proteins.
The company is primarily developing these therapies for the treatment of solid tumours, with a pipeline that includes targeted cancer therapies and radiopharmaceuticals aimed at improving treatment effectiveness while reducing side effects.
For the second quarter, the company narrowed its net loss by 36% to $50.33 million from $78.95 million in the previous year.
Loss per share shrank to $0.72 per share from $1.14 per share a year earlier.
Collaboration revenue for the second quarter fell to $0.63 million from $2.92 million in the corresponding quarter of 2025.
Cash and cash equivalents totalled $510.05 million as of June 30, 2026.
The company expects to begin its first company sponsored clinical trial of the radioligand candidate BT1702 for MT1-MMP positive solid tumors.
BCYC closed Thursday's trade at $4.01, up 3.89%. In after-hours trading, shares are up 0.25% at $4.02.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.